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Isoniazid though a very effective treatment for
tuberculosis can cause severe motor-dominant
neuropathy which can be reversible with pyridoxine
supplementation. A 45-year-old female diagnosed with
psoas abscess, culture positive for mycobacterium
tuberculosis, was started on anti- tuberculous treatment
with four drugs, including isoniazid at a dose of 5
mg/kg/day. Three months later she developed severe
motor weakness of lower limbs with loss of ankle and
knee reflexes. She was treated with vitamin B6 injections
and isoniazid treatment was continued. Her motor
weakness gradually improved in a few months, but mild
sensory impairment persisted even after two years. There
is need for vigilance regarding neurological effects of
isoniazid in seemingly low-risk individuals in whom
development of symptoms should raise the suspicion
about slow acetylator status. Timely therapeutic
intervention with high-dose vitamin B6 can reduce the
long-term morbidity associated with this easily reversible
condition.
Keywords: Isoniazid, Neuropathy, Pyridoxine, Anti
tuberculous therapy.
Introduction
The World Health Organisation (WHO) ranks Pakistan 5th
among the "high tuberculosis (TB) burden countries".
About 420,000 new cases are reported every year in the
country1 and most patients are treated with
recommended first-line anti-TB drugs that include
isonicotinylhydrazine (INH) or isoniazid, rifampicin,
pyrazinamide, ethambutol and streptomycin. Isoniazid
typically causes a sensory peripheral neuropathy which
presents with burning and numbness of the extremities.
In a few cases, sensory symptoms may progress rapidly
with the development of ataxia and motor weakness.
Isoniazid acts as a competitive inhibitor of pyridoxine (B6),
making its biologically active form less available for
proper functioning of nerve cells.2
The incidence of isoniazid-induced neuropathy is very
low, ranging from 0.2-2% in the general population.2 This
susceptibility appears to be highest in the elderly, during
pregnancy, in chronic alcoholics, malnourished, human
immunodeciciency virus (HIV) infected individuals and
patients with slow acetylator genotype.3 Therefore
guidelines recommend vitamin B6 prophylaxis only for
the above-mentioned high-risk patients.4-6
In line with a case reported from Tunisia in 2012,4 we
report a case of a middle aged female who developed
severe axonal sensory and motor neuropathy leading to
quadriparesis three months after she was started on anti-
TB treatment (ATT) without vitamin B6 prophylaxis.
Case Report
A 45-year-old woman, a teacher by profession, presented
with sudden onset of numbness and muscle weakness of
limbs with one-week history. Her symptoms had started
with difficulty in rising from a chair progressing to
weakness of the upper limbs as well. She had been
diagnosed with a psoas abscess three months earlier at a
local hospital that was drained and was found to be
culture-positive for mycobacterium tuberculosis after
which the intensive phase of ATT using four drugs
(isoniazid 5mg/kg, rifampicin 10mg/kg, pyrazinamide
25mg/kg and ethambutol15mg/kg) was given for two
months. Her symptoms started during the early part of
her continuation phase with two drugs (isoniazid and
rifampicin). She did not receive any vitamin B6
supplementation alongside ATT. Her only co-morbid
condition at the time of treatment was hypertension
which was controlled on an angiotensin-converting-
enzyme (ACE) inhibitor lisinopril10mg. The patient had no
history of immunodeficiency, diabetes, renal failure,
hepatic dysfunction, human immunodeficiency virus
(HIV) infection. She was a non-smoker and did not use
alcohol. She denied any recent upper respiratory tract
infections or fever. She appeared to be recovering well
from her tuberculosis infection as evident from a history
of weight-gain and resolution of fever. She presented to
the clinic in a wheelchair unable to walk or bear weight.
Her vitals were stable with a body mass index (BMI) of
26kg/m2. General physical examination was
unremarkable. Neurological examination revealed
sensorimotor tetra paresis with a muscle strength of 4/5 in
all extremities. Achilles and patellar tendon reflexes were
reduced. Peripheral joints were free. There were
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decreased touch sensations with total loss of
proprioception in both upper and lower limbs. Cranial
nerves were intact. There was no deglutition or breathing
difficulty. With symptoms involving all four limbs, she was
diagnosed with INH-induced B6 deficiency with a
differential of Guillian Barre Syndrome (GBS). An urgent
consultation was sought from neurologist and she was
empirically started on vitamin B6 injections.
A complete blood count (CBC) ordered at the time of
presentation showed mildly low haemoglobin of
10.2gm/dl. All other laboratory investigations, including
lactate dehydrogenase (LDH), creatinephosphokinase
(CPK), erythrocyte sedimentation rate (ESR), liver enzymes
Alanine transaminase (ALT) and thyroid stimulating
hormone (TSH) were within normal limits.
Electromyography was also ordered which showed severe
axonal sensorimotor polyneuropathy with slow
conduction velocities of bilateral peroneal motor nerves
and nerves supplying right tibias anterior muscle. After
review of all investigations, injectable vitamin B complex
was continued, and amitriptyline gabapentin was
prescribed for neuropathic pain. Physiotherapy was
initiated. The patient showed rapid improvement in
muscle weakness oneweek after initiation of B6 injections
by demonstrating an ability to stand on her own.
Subsequent visits showed further improvement with
increasing ability to bear weight and ambulate. She was
later switched to oral pyridoxine at a dose of 100mg/day
and physiotherapy was continued. Over the next several
months she continued to show improvement with
decreasing motor dysfunction. She, however, continued
to have mild sensory deficit in all limbs, lower more than
upper, and power deficit in the small muscles of her feet.
At two-year follow-up she was able to climb stairs with
minor difficulty, but continued to have mild numbness
and tingling in her toes. Power returned to 5/5 in both
upper and lower limbs.
Discussion
Numerous studies have identified isoniazid as a cause for
peripheral neuropathy.2,3 Practically, however, the
incidence of peripheral neuropathy among patients
receiving isoniazid at conventional doses is reported to be
very low, ranging from 0.2-2%.3 This neuropathy is most
common in high-risk patient population that includes
slow acetylators, patients with HIV, diabetes, chronic renal
failure, pregnant and lactating women, malnourished and
elderly patients, alcoholics, patient on certain
medications that antagonize B6 effect like hydralazine,
cycloserine, penicillamine and antiretroviral drugs.2,3 The
guidelines of WHO, Centers for Disease Control and
Prevention(CDC), the American Thoracic Society (ATS),
therefore, recommend 10-25mg per day pyridoxine
prophylaxis along with isoniazid to prevent the onset of
neuropathy in these high-risk groups.4,5 Local guidelines
from Pakistan also do not recommend B6 prophylaxis for
low-risk groups despite this disease being highly
endemic.6 Our patient despite being a low-risk candidate
for INH-induced neuropathy developed severe motor
dominant polyneuropathy that was later on reversed with
pyridoxine supplementation.
There is no report to our knowledge that patients with no
risk factors developed severe motor dominant
neuropathy after the use of isoniazid. However, literature
search has identified two case reports of isoniazid-
induced neuropathy in the presence of one or more
underlying risk factors. The first, published in 2006,
mentioned the case of a 42-year-old French female,
diagnosed as HIV, who developed sensori-motor
neuropathy three months after commencement of
isoniazid therapy for presumed tuberculosis. Assuming a
slow acetylator status for her, the dose of INH was
reduced, and vitamin B6 supplementation resolved the
neuropathy completely.7 The second case report
published in 2012 in Tunisia described a patient who
developed motor neuropathy just two weeks after the
start of INH.8 In this case, however, a BMI of 18kg/m2 may
have contributed to an increased risk of neuropathy. In
our case the nutritional status as well as BMI were well
within normal range. In the absence of a low BMI and
known co-morbidities, low acetylator status of our patient
was another consideration, but laboratory testing is not
readily available to check acetylator status in our part of
the world.
National and regional guidelines on tuberculosis do not
recommend pyridoxine prophylaxis in low-risk patients
probably as it adds approximately Rs1500 (USD15.2) per
patient for every six months of treatment. In addition, the
low incidence of neuropathy with isoniazid use and its
reversibility with therapeutic doses of pyridoxine goes
against the argument of routine prescription of
pyridoxine as prophylaxis.
However, a concern in our part of the world is that many
patients get lost to follow-up or present late after
symptoms manifest, primarily due to financial reasons or
lack of health awareness. Would it be prudent, therefore,
to also provide prophylaxis to low-risk patients who have
poor health awareness, an understanding of drug side
effects and are at risk for getting lost to follow-up?
Another question arises whether presence of other
micronutrient deficiencies commonly found here makes
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patients more vulnerable to the side effects of ATT.
Our patient, despite getting a timely diagnosis and
treatment, recovered but was left with some residual
deficits.
The solution maybe for physicians to perform a
meticulous review of risk factors in all patients
undergoing ATT without pyridoxine supplementation,
educate them regarding potential side effects of ATT so
that they may seek early medical attention.
Conclusion
The case highlights the need for vigilance regarding
neurological effects of INH in seemingly low-risk
individuals. Healthcare providers need to assess
nutritional status before starting ATT. More importantly,
all patients receiving ATT should be educated about the
risk of neurological side-effects of INH and the need for
early reporting so that timely therapeutic intervention
can reduce the long-term morbidity associated with this
easily reversible albeit rare condition.
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